Q106983497
Dotaz
Zobrazit nápovědu
By December 2019, humanity was challenged by a new infectious respiratory disease named coronavirus disease of 2019 or COVID-19. This is a viral infection based on the presence of the previously non-problematic coronavirus with assigned number 2. This virus causes severe acute respiratory distress and is known now as SARS-CoV2. Since SARS-CoV2 is an RNA virus, remdesivir and favipiravir, both broad-spectrum RNA polymerase inhibitors, were repurposed for treating COVID-19 patients. Remdesivir and favipiravir are antimetabolites, and they are structurally related to the naturally occurring structural elements of RNA. Both agents are prodrugs and must be activated intracellularly to exert their effects through numerous and different mechanisms of action. Efforts have been exerted to determine their efficacy and safety against COVID-19 through clinical trials. Clinical trials have shown an association of remdesivir with increased frequency of adverse effects (in comparison to favipiravir). Nevertheless, the data obtained with remdesivir resulted in its approval by the FDA on the 22nd of October 2020 for COVID-19 treatment. At present, remdesivir is being recommended by several treatment guidelines for the treatment of COVID-19 patients. The evidence in favor of favipiravir is compromised by the small number and low-quality of trials conducted. Favipiravir has shown various benefits when administered in mild and moderate cases of COVID-19, while remdesivir was more beneficial in more severe cases of the disease. Since the two agents are suitable for different groups of patients, both drugs can play a significant role in fighting this pandemic. The goal of this work is to summarize the information available on two antimetabolites - remdesivir and favipiravir - and to compare clinical experience obtained so far with these two agents in COVID-19 patients.
To evaluate the preclinical efficacy and safety of human mesenchymal stem cells (hMSC) rapidly expanded in growth medium for clinical use with human serum and recombinant growth factors, we conducted a controlled, randomized trial of plasma clots with hMSC vs. plasma clots only in critical segmental femoral defects in rnu/rnu immunodeficient rats. X-ray, microCT and histomorphometrical evaluation were performed at 8 and 16 weeks. MSC were obtained from healthy volunteers and patients with lymphoid malignancy. Human MSC survived in the defect for the entire duration of the trial. MSC from healthy volunteers, in contrast to hMSC from cancer patients, significantly improved bone healing at 8, but not 16 weeks. However, at 16 weeks, hMSC significantly improved vasculogenesis in residual defect. We conclude that hMSC from healthy donors significantly contributed to the healing of bone defects at 8 weeks and to the vascularisation of residual connective tissue for up to 16 weeks. We found the administration of hMSC to be safe, as no adverse reaction to human cells at the site of implantation and no evidence of migration of hMSC to distant organs was detected.
- MeSH
- dospělí MeSH
- femur diagnostické zobrazování fyziologie MeSH
- hojení ran fyziologie MeSH
- krysa rodu rattus MeSH
- lidé středního věku MeSH
- lidé MeSH
- mezenchymální kmenové buňky fyziologie MeSH
- náhodné rozdělení MeSH
- osteogeneze fyziologie MeSH
- počítačová rentgenová tomografie metody MeSH
- potkani nazí MeSH
- senioři MeSH
- syndromy imunologické nedostatečnosti diagnostické zobrazování imunologie terapie MeSH
- transplantace mezenchymálních kmenových buněk metody MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- dospělí MeSH
- krysa rodu rattus MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Závěrečná zpráva o řešení grantu Interní grantové agentury MZ ČR
Přeruš. str. : il., tab. ; 32 cm
Výzkum a vývoj voltametrické,polarografické a příbuzné elektroanalytické metodiky,instrumentace,pracovních postupů a software pro stanovení vybraných biologicky aktivních látek a jejich metabolitů,zejména na bázi chlorovaných uhlovodíků a bipyridilů . Nové možnosti polarografické a voltametrické analýzy vybraných biolgicky aktivních látek v toxikologicky zajímavých systémech.Vytvoření odpovídající laboratoře pro výzkum a aplikaci. New poáibilities of polarographic and voltammetric analysis of selectedbiologically active compouds in toxicologically important systems. Establishment of a laboratory appropriate for basic and applied research.; Research and development of the polarographic and voltammetric methods and instrumentation (including special accessories), of working procedures and of the pertaining software for determination of selected biologically active substances.
- MeSH
- arsen toxicita analýza MeSH
- olovo toxicita analýza MeSH
- polarografie přístrojové vybavení využití metody MeSH
- potenciometrie přístrojové vybavení využití metody MeSH
- rtuť toxicita analýza MeSH
- vinylchlorid toxicita analýza MeSH
- Konspekt
- Chemie. Mineralogické vědy
- NLK Obory
- chemie, klinická chemie
- toxikologie
- NLK Publikační typ
- závěrečné zprávy o řešení grantu IGA MZ ČR
